You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for C25-140
C25-140 binds directly to TNF receptor-associated factor 6 (TRAF6) and inhibits its interaction with ubiquitin-conjugating enzyme Ubc13. C25-140 reduces TRAF6-Ubc13 activity and decreases NF-κB activation and inflammatory signaling in vitro. C25-140 exhibits selectivity for TRAF6 over other E3 ligases except cIAP1. In in vivo mouse models of autoimmune psoriasis and rheumatoid arthritis, the compound improves disease symptoms. The compound also suppresses the pro-inflammatory signaling activity of IL-17A and prevents its inhibitory effect on the anti-HBV action of IFN-α HepG2 cells.
Technical Data for C25-140
|Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for C25-140
|Max Conc. mg/mL
|Max Conc. mM
Preparing Stock Solutions for C25-140
The following data is based on the product molecular weight 457.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass
References for C25-140
References are publications that support the biological activity of the product.
Brenke et al (2018) Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J.Biol.Chem. 293 13191 PMID: 29950522
Zhang et al (2022) Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells. Virol.J. 19 28 PMID: 35144643
If you know of a relevant reference for C25-140, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: C25-140, C25-140 supplier, inhibits, inhibitors, TRAF6-Ubc13, NF-kB, NF-KappaB, κ, E3, ligases, Ubiquitin, Ligases, NF-kB/IkB, 7715, Tocris Bioscience
Citations for C25-140
Citations are publications that use Tocris products.
Currently there are no citations for C25-140. Do you know of a great paper that uses C25-140 from Tocris? Please let us know.
Reviews for C25-140
There are currently no reviews for this product. Be the first to review C25-140 and earn rewards!
Have you used C25-140?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Targeted Protein Degradation Research Product GuideUpdated
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- TAG Degradation Platform
- Degrader Building Blocks
- Ubiquitin-Proteasome System Proteins
- Assays for Protein Degradation
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia